Ursodiol disulfate
Alternative Names: Disulfate conjugate of ursodeoxycholate (SUDCA); SUDCA; Ursodeoxycholic acid-disulfateLatest Information Update: 11 Aug 2011
At a glance
- Originator Cincinnati Childrens Hospital Medical Center
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Colorectal cancer; Liver transplant rejection
Most Recent Events
- 25 Feb 2008 Axcan Pharma has been acquired by Texas Pacific Group
- 23 Feb 2007 Discontinued - Preclinical for Liver transplant rejection in Canada (IV)
- 30 Sep 2006 Axcan completes a second phase I trial in Colorectal cancer in Canada